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Developments in biotechnology have radically altered clinical and research themes in
the small ﬁeld of disorders of sex development, as in other rare medical conditions.
In the age of genetics, an increasing number of DSDs have been identiﬁed. Aided by
larger populations of people with DSD diagnoses attending specialist centres, these dis-
coveries are enabling medical doctors and scientists to map out the long-term clinical
presentations of a number of conditions. In terms of beneﬁts to patients, the new discov-
eries have paid dividends in two speciﬁc ways. First of all, even though knowledge may
remain incomplete, our understanding of the risk of malignancy in retained gonads has
improved signiﬁcantly. Consequently, care providers are in a stronger position than they
have ever been to advise patients in their decision-making processes around removing
or retaining their gonads. Second, more scientiﬁc understanding has led to improved
fertility outcomes for women who have a uterus, as in Turner’s Syndrome, Congenital
adrenal hyperplasia and Swyer’s Syndrome.
Keywords: Turner syndrome; congenital adrenal hyperplasia; Swyer syndrome;
cloacal exstrophy
Introduction
In recent years, the scientiﬁc drive in the ﬁeld of DSD has focused on identifying new gene
variations (mutations) that lead to atypical sex development. There is often then a time lag
between such genetic discovery and routine genetic screening with larger populations. Now
that automated gene sequencing is available in many biochemistry departments, however,
the identiﬁcation of genetic variations as part of a routine medical work up is becoming
more common. The next phase of development of our knowledge base for DSDs will be in
identifying subtleties of physical health characteristics and long-term physical health risks
of each genetic group.
Some individuals with a DSD diagnosis may ﬁnd genetic research an esoteric subject
with little relevance for their well-being. However, the scientiﬁc agenda is often driven by
pertinent medical issues. First of all, there are families with several members who have a
DSD diagnosis and these families may also have individuals who carry a variant gene or
a group of variant genes. This topic is currently especially relevant to those diagnoses that
are associated with male-typical XY (sex) chromosomes. Individuals with these diagnoses
present to a greater or lesser extent male-typical physical sex characteristics, such as a
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Table 1. A summary of the new nomenclature relating to disorders of sex development.
Previous Current
Intersex Disorder of Sex Development DSD
XY sex reversal 46,XY gonadal dysgenesis
Male pseudohermaphrodite
Undervirilisated XY male
46,XY DSD
Female pseudohermaphrodite
Masculinised XX female
46,XX DSD
True hermaphrodite Ovotesticular DSD
XX male, XX sex reversal 46,XX testicular DSD
signiﬁcant amount of facial and body hair, enlargement of the clitoris and deepening of the
voice. Second, it may be possible to identify patterns of health concerns that could affect
long-term follow-up once we know how to differentiate one condition from another at the
genetic level.
Rather than going into the detail of each new genetic variant in the physical sex dif-
ferentiation pathway, this overview will discuss the common conditions that come under
the heading of DSD and then review the advances that affect medical management derived
from experience in a tertiary multidisciplinary DSD clinic. Detailed reviews of new genetic
variations in the pathway of sex differentiations can be found in several recent papers
(Bashamboo, Ledig, Wieacker, Achermann, & McElreavey, 2010; Ludbrook & Harley,
2011) and will not be repeated here.
Scientiﬁc progress will also be promoted by the increasing popular strategy of collab-
orating groups of clinicians combining knowledge of larger cohorts of individuals with
DSD diagnoses so that long-term outcomes can be documented. As DSDs are rare condi-
tions, it is important to construct larger cohorts so that the spectrum of variability on each
condition can be documented. An international collaboration entitled iDSD is one such
initiative. This work will allow for greater conﬁdence and speed of diagnosis for new cases
as they arise. Table 1 shows the current nomenclature for the classiﬁcation of DSD. This
overview also considers related conditions outside of the current classiﬁcation including
Turner’s Syndrome and Klinefelter’s Syndrome.
Sex chromosome DSD
DSD diagnoses triggered by variations in the sex chromosomes (46,XX being female typ-
ical and 46,XY male typical) are associated with absent development or early demise of
the gonads that would otherwise develop into testes or ovaries. Technical advances in this
ﬁeld include the use of probes to identify the number of X and Y chromosomes within
24 hours. For example, XXY is likely to mean Klinefelter’s Syndrome. The application of
these techniques to identify variations in foetal sex chromosomes by testing amniotic ﬂuid
taken from the womb during pregnancy could pose ethical challenges when offering infor-
mation that could affect parental decision whether or not to continue with the pregnancy.
This is especially so when the genetic make-up is not a strong predictor of the develop-
mental outcome. For example, an individual with Turner’s Syndrome may enjoy relatively
good health with regular ovarian function at puberty, or present serious and multiple health
problems across the lifespan.
Another scientiﬁc advance in this area relates to the fertility outcomes for this group
of conditions. In Turner’s syndrome (TS), which affects only females and is caused by
D
o
w
n
l
o
a
d
e
d
 
b
y
 
[
U
n
i
v
e
r
s
i
t
y
 
C
o
l
l
e
g
e
 
L
o
n
d
o
n
]
 
a
t
 
0
9
:
0
8
 
3
0
 
J
a
n
u
a
r
y
 
2
0
1
5
 30 G.S. Conway
complete or partial absence of the 2nd X chromosome, approximately 20% of the girls can
expect to enter puberty as is typical and have preserved ovarian function that may continue
for several years. Previously, no medical help could be offered to this group, apart from
monitoring the progress of early loss of ovarian function. With improved techniques in egg
freezing, it is now possible to harvest eggs for preservation and future use (Balen, Harris,
Chambers, & Picton, 2010; El-Shawarby, Sharif, Conway, Serhal, & Davies, 2010). For the
80% of the TS population without ovarian function and therefore no periods ever and for
whom hormonal induction of puberty is required, the wider application of egg donation
has allowed many more women to conceive. As we have more information now about the
health risks of adult women with TS, we are also increasingly aware of the risk of tearing
in the wall of the major blood vessel that can lead to rupture of the heart and sudden
death during pregnancy. Therefore, for women choosing egg donation, the whole process
of fertility for women with TS has to be carefully managed in a multidisciplinary service
(Chalas Boissonnas et al., 2011). The case reports may well have overestimated the health
risks of conception via egg donation in TS compared to population-based studies which
show good obstetric outcomes (Hagman et al., 2011).
For men with Klinefelter’s syndrome, a relatively common form of DSD affecting one
in 500 men, the most dramatic advance has been in retrieving viable sperm from the testes
(Schiff et al., 2005). Until the advent of micro-testicular sperm extraction techniques, there
was no available treatment for the usual presentation of absence of sperm in the ejac-
ulate of men diagnosed with Klinefelter’s syndrome. Several research groups are now
reporting retrieval rate of viable sperm in up to 50% of individuals using a painstaking
technique whereby the testis is opened and the small tubular structures where sperm can
be found are individually inspected under a microscope for the presence of sperm (Schiff
et al., 2005; Vernaeve et al., 2004). A single sperm thus retrieved can be injected into a
single egg which has been harvested in the context of in vitro fertilisation. Replication
of this success rate by other units will be required before we know more about fertility
outcome.
46,XY DSD
46,XY DSD covers three main external anatomical presentations: 46,XY gonadal dysgen-
esis, androgen insensitivity syndrome and testosterone biosynthesis conditions. A variety
of rare conditions that come under this heading are listed in genetic reviews cited above.
Women with 46,XY gonadal dysgenesis (Swyer’s syndrome) have gonads that are nei-
ther testes nor ovaries, because disruption to regular sex differentiation occurs very early
on in embryonic life. The women therefore do not experience menstrual periods ever and
do not experience the usual pubertal development in adolescence. Furthermore, the gonads
have to be removed because of the high-risk of malignancy. Lifelong oestrogen replace-
ment therapy is required to maintain health. Development of the uterus however does take
place and there are now increasing reports showing that pregnancy achieved through egg
donation is highly successful (Creatsas, Deligeoroglou, Tsimaris, Pantos, & Kreatsa, 2011;
Michala, Goswami, Creighton, & Conway, 2008; Tulic, Tulic, & Micic, 2011).
Complete androgen insensitivity syndrome (CAIS) is due to a problem with the andro-
gen reception gene. Individuals with male-typical (46,XY) sex chromosomes do not have
receptors to respond to androgens secreted by the testes. When development of male-
typical sex characteristics is absent, the external anatomy is female-typical. Internally, the
individual has testes and is without a womb or cervix and a smaller than average vagina.
Nearly all individuals diagnosed with CAIS are female assigned and identiﬁed.
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Our understanding of CAIS has improved by the study of larger cohorts. In particular,
it is now recognised that the risk of malignancy of the testes is considerably less for this
condition than for other forms of 46,XY DSD (Cools & Looijenga, 2011). For instance,
it is estimated that the risk of gonadal malignancy in CAIS is less than 1% compared to
approximately 25% for women with Swyer’s syndrome (Cools et al., 2005; Pleskacova
et al., 2010). This clariﬁcation has led to some women with CAIS choosing to retain their
testes that are producing steroids to keep them healthy, thereby avoiding the need for long-
term oestrogen replacement therapy. It is also noted however that the data on gonadal risk
is based on paediatric data and may not hold true for women in an older age group (Deans,
Creighton, Liao, & Conway, 2012). Further research is required to ﬁnd how we can advise
women with CAIS as to how safe it is to avoid gonadectomy.
Until recently, women with a 46,XY DSD diagnosis associated with some male-typical
sex characteristics (e.g. ambiguous genitalia at birth) were believed to have partial andro-
gen insensitivity syndrome (PAIS), that is, they are partially receptive to the androgen that
stimulate development of male-typical sex characteristics (Inacio et al., 2011). With the
wider application of genetic analysis and studies of proﬁles of steroid in the urine, it is now
recognised that only a minority of cases are to do with problems of the androgen recep-
tor gene. Some of these conditions overlap completely with two testosterone biosynthesis
conditions: 5 alpha reductase deﬁciency and 17 hydroxysteroid dehydrogenase deﬁciency
(Berra et al., 2011). Greater understanding of the natural history of each condition can
now develop and retrospective assessment might allow for better clinical identiﬁcation of
conditions when they are ﬁrst presented.
Currently, there is a lot of interest in changes to the NR5A1 (SF1) gene in some 46XY
DSD conditions. It is thought that NR5A1 mutation accounts for about 15% of identiﬁed
cases of 46,XY DSD. However, it is also becoming clear that there is a spectrum of physical
features associated with this genetic variation (Ludbrook & Harley, 2011).
One of the major areas for future research on all forms of 46XY DSD is the integrity
of the germ cells – cells within the ovary or testis that eventually develop into eggs or
sperm. As such fertility options might be considered before removal of the gonads to
reduce cancer risks. So far, no reports of preservation of germ cells have emerged, but this
will be an area to watch as the long-term outcome of well-described conditions become
clear.
46,XX DSD
The most common form of 46,XX DSD is the group of metabolic conditions called con-
genital adrenal hyperplasia (CAH), for which the medically necessary treatment is with
adrenal steroid, a group name for ﬂudrocortisone, hydrocortisone, prednisolone and dex-
amethasone. CAH affects both females and males. Once again, the main progress in our
understanding of CAH comes from increasing data from adult cohorts. A major scientiﬁc
advance has been the improved fertility outcomes for women with CAH. Fertility used to
be dismal, but is now essentially much less of a problem as a result of attention to detail in
adrenal steroid treatment (Casteras, De Silva, Rumsby, & Conway, 2009; Hagenfeldt et al.,
2008).
While girls and women with CAH may have additional psychological challenges com-
pared to their male counterparts, due to the effects on sex anatomy, there is a major concern
of the persistently poor fertility outcomes in men (Reisch et al., 2009). Testicular adrenal
rest tissues (TARTs) are small nodules in the testis and cause damage because they displace
testicular tissue. Testicular failure is common with only a minority of men having sperm
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counts with fertility potential. Early education and secure transition to adult services will
be important in improving management of males with CAH (Falhammar et al., 2012).
Cloacal exstrophy
Cloacal exstrophy is a rare, highly complex condition and a life threatening condition
affecting about 1 in 200,000 live births, with a spectrum of anatomical variations affecting
multiple organ systems. Survival rates have improved in recent decades. However, there
is much to learn as more individuals survive into adulthood. Surgical management typi-
cally involves multiple medically essential operations throughout the life span. In general,
the advent of multidisciplinary care has shifted the focus to minimise medically non-
essential surgery at young ages so as to keep options open for informed choices later in
life. Feedback from older age groups (Reiner & Gearhart, 2004) has allowed for more
accurate prediction of gender orientation. In contrast to earlier emphasis on female gender
assignment, there is now a greater openness towards male gender assignment.
Conclusions
Specialisation of clinical services and improved information have increased our knowledge
of the natural history of DSDs. Faster and more extensive biogenetic technology, with
the introduction of whole genome sequencing, is predicted to advance our knowledge of
genetic changes that lead to certain anatomical outcomes associated with DSD. There are
initiatives in a number of countries that aim to develop care pathways for rare conditions,
informed by an accelerated user movement. These care pathways will facilitate further
audit and research, leading to more molecular discoveries and probably changes to medical
treatment and clinical care more generally in the next 10 years.
Notes on contributor
Professor Conway is a consultant endocrinologist at University College London Hospitals and
professor of clinical medicine in the Institute for Women’s Health, University College London.
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